Dallas, TX April 27, 2016 – Cerebain Biotech (OTCQB: CBBT) today announced that the company intends to seek FDA approval in conjunction with the development and testing of its medical device for the treatment of Alzheimer’s and Dementia.
The Company has reached a decisive point in their research and is planning to commence development of the device. As previously expressed, the Company has three options for implantable devices with a bias towards having them as non-invasive as possible. It is theorized that if a patient’s response to the omentum stimulation is successful, the clinical facility should be able to perform various tests for the purpose of setting “markers” for the patient and then perform the standardized cognitive testing for Alzheimer’s patients.
Eric Clemons, president and CEO of Cerebain, stated “It is vital we identify an individual to create our surgical manual for device implantation who has a broad perspective on the Global Healthcare System and its challenges. Their experience must encompass public, private and academic settings, with proficiencies in public health, statistics and clinical research”. Mr. Clemons further stated “We have entered into discussions with a prominent Medical Doctor we deem demonstrates these stringent guidelines.”
Scott McCallum, former Governor of Wisconsin, has initiated discussions pertaining to the representation of the Company in Poland for the purpose of Clinical Testing of the Company’s Medical Device for the treatment of Alzheimer’s disease utilizing the Omentum. The purpose of these discussions is to determine and finalize any required local approvals and establish essential partnerships with Doctors and Medical Facilities necessary for this testing.
The Company has engaged the services of Hamilton Advisors of Great Falls, VA, to support business development goals that will help the company accelerate its research programs, with an emphasis on receiving FDA approval.
About Cerebain Biotech Corp.
Cerebain Biotech (OTCQB: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations.
Forward Looking Statements
This news release contains certain “forward- looking statements.” Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company’s control. The forward-looking statements are also identified through the use of words “believe,” enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company’s reports filed with OTC Markets. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved.